InterbrandHealth Report Reveals Top Biopharma Brands: Leaders Are Addressing Needs of Healthcare Professionals to Tackle the Challenges of Today

NEW YORK–(BUSINESS WIRE)– A global study released today by InterbrandHealth identifies the
biopharma companies that are addressing healthcare professionals’
(HCPs), payers’, and policymakers’ needs. A commitment to brand is a
promise to address healthcare challenges and meet the needs of these
healthcare professionals.

The study examines what value means to HCPs and illustrates the
influence the corporate brand has in conveying that value. It reveals
how leading companies are beginning to deliver on what matters to HCPs.

Looking to the future, healthcare professionals desire a commitment to
innovative healthcare solutions that go “beyond the pill.” As a result,
leading biopharma companies are adapting their business models,
increasing transparency, exploring nontraditional solutions in areas
like digital therapies, and ramping up their corporate citizenship
activities.

“Biopharma is at a pivotal moment, and the time for change is now,” said
Jane Parker, InterbrandHealth’s CEO.

Dr. Ronnie Hershman, a cardiologist affiliated with NYU Langone Long
Island Cardiac Care and the CEO of HealthEffect, LLC, noted, “The
biopharma industry has relied on blockbuster drugs for a long time, but
healthcare is changing, and what physicians need has changed. Biopharma
companies need to shift and think about what else they can offer.”

Best Pharma Brands ranks these leading companies by qualifying the
industry’s definition of value through brand, then quantifying the
corporate brand’s contribution to business performance. The ranking
identifies the 10 most valuable biopharma brands. In total, these 10
brands represent approximately USD $129 billion in brand value. Pfizer
and the Roche Group secure the #1 and #2 positions on the ranking.

Best Pharma Brands Ranking

*The ranking and brand value for each organization is outlined below

• #1 Pfizer (USD $19.985 billion)
• #2 Roche Group (USD $15.479 billion)
• #3 Merck & Co., Inc., Kenilworth, N.J., U.S.A. (USD $13.880 billion)
  [Note:
  MSD outside of the United States & Canada]
• #4 Janssen: Pharmaceutical Companies of Johnson & Johnson (USD $13.866
  billion)
• #5 Novartis (USD $13.496 billion)
• #6 Amgen (USD $13.461 billion)
• #7 Gilead Sciences (USD $13.361 billion)
• #8 Novo Nordisk (USD $10.206 billion)
• #9 AstraZeneca (USD $8.123 billion)
• #10 GSK (USD $6.778 billion)

Best Pharma Brands also sets an important industry benchmark by
highlighting the need for biopharma companies to change how they
interact with the market and meet the needs of the healthcare community.

Parker commented that “these 10 biopharma brands are embracing a
strategy that is somewhat new to the health and life sciences sector:
they are effectively leveraging their corporate brands and, in doing so,
they are growing their businesses, fueling innovation, and developing
meaningful solutions for patients on a global scale.”

Best Pharma Brands is powered by global research data, feedback from
HCPs, and data-driven insights. The underlying methodology mirrors
Interbrand’s Best Global Brands, which demonstrates that strong brands
can withstand market volatility and are more likely to outperform key
financial indices like the S&P 500.

To be considered, biopharma brands must have a global presence, generate
revenue from the sale of prescription medicines, report the ratio of
revenues generated from sales of prescription medicines, possess a
strong pipeline of potential future prescription medicines, have
awareness among HCPs, and serve as the primary external-facing
manufacturer brand.

Please visit BestPharmaBrands.com
to request a download of the report. To join the conversation on social
media, use the hashtag #BestPharmaBrands.

About Best Pharma Brands

Best Pharma Brands is InterbrandHealth’s inaugural top 10 ranking that
quantifies the corporate brand’s contribution to business performance in
the biopharma industry.

Best Pharma Brands is powered by Interbrand’s International Organization
for Standardization (ISO)–certified Brand Valuation methodology, which
quantifies the measurable financial impact that a company’s brand has on
its overall business performance.

Best Pharma Brands reflects HCPs’ current perceptions of brand value,
measured through a global online survey. The report focuses on the
prescription portion of a biopharma company’s total revenue. Other
revenue sources, including consumer health, over-the-counter products,
medical device sales, diagnostics, and animal health are excluded from
the analysis.

In addition to the ranking and supporting commentary, the report
examines industry trends and provides data-driven insights on topics
such as the impact of the corporate brand in an adoption decision,
mergers and acquisitions, and corporate citizenship. The report clearly
outlines how corporate brand, when leveraged, can generate significant
value for a business.

About InterbrandHealth

InterbrandHealth is the only full-service branding consultancy with an
exclusive focus on health, and the global center of excellence for all
health business at Interbrand. For more than 35 years, InterbrandHealth
has combined strategy, creativity, and analytical rigor to help
companies grow and achieve leadership positions in their industries.

As the leader in brand valuation and the publisher of the annual Best
Global Brands report, Interbrand has pioneered the idea that brands have
a tangible value as business assets. As part of Interbrand and the
Omnicom Group Inc. (NYSE:OMC), InterbrandHealth provides service and
support in all key global markets. For more information, please visit us
at InterbrandHealth.com
and follow us on Twitter, LinkedIn, and Facebook.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160329006676/en/